Atracurium has an unusual intrinsic Hofmann elimination which is increased by an alkaline environment and increased temperature. Normally the relaxant is stored at pH 3.3 and kept at a temperature of 4°C. However, it is convenient to have a reasonable quantity available within the operating theatre. This study examined the rate of degradation of atracurium in the operating theatre environment of 20°C.
Atracurium besylate has an unusual intrinsic Hofmann elimination which increases in an alkaline environment and at elevated temperature. The recommended storage condition of the relaxant solution which is stabilised to pH 3.3 is a temperature of 4°C. However, in clinical practice it is not usually convenient to have all the atracurium stored in the refrigerator.
If reasonable stability at 20°C for a few weeks or months could be demonstrated, it would be a practical advantage as a limited quantity could be kept with the anaesthetic machine or in the drug trolley.
Laboratory information supplied by the manufacturer, Welicome, suggested that atracurium besylate should be fairly stable at room temperature. In addition, consideration of the pharmacokinetic elimination in man and the likely contributions of pH and temperature to the degradation also supported the hypothesis of reasonable stability at room temperature in an acid environment.
This investigation was planned to study the stability of atracurium stored under normal operating theatre conditions for up to three months.
METHODS
Ampoules of atracurium besylate from a single batch which was within one month of its expiry date (eighteen months from manufacture) were individually and randomly coded. A set of three ampoules was placed in each of three operating theatres. All theatres have good air-conditioning and are stabilized to within one or two degrees of 20°C. Twenty-nine days later, a further set of ampoules was placed in each theatre with the first set. Thirty-six days later, a further set of ampoules was placed in each theatre with the others. After a further twenty-eight days all ampoules were withdrawn from the operating theatres and placed in the refrigerator at 4°C and kept in cool storage for a further 33 days until assayed ( Figure 1 ). As a further check, nine ampoules from a current batch about four months from manufacture were also coded and sent for assay.
Assay was performed by high-pressure liquid chromatography by Wellcome Australia under blind conditions. In this assay, the sample is diluted ten times with an eluent of acetonitrile : water : phosphoric acid (SO 1. 7 5) 900 : 90 : 10, and a 10 microlitre sample is injected into a Partisil 5 column using a pressure of 10 MPa at ambient temperature with a UV detector at 280 nm. The seven known breakdown products and atracurium were detected with retention times from 3.6 to 11.9 minutes. The related substances and retention times are listed in Table 1 . Percentage related substances are calculated as the percentage related substances peak areas divided by the total peak
Atracurium besylate areas (related substances and atracurium). Percentage atracurium was calculated from the original level of atracurium at manufacture less the proportional increase in related substances.
RESULTS
In total, forty-two ampoules were assayed. Some ampoules which were exposed to theatre conditions were lost (?used) and were not available for assay. The mean level of related substances and the standard deviation are given in Table 2 . From this table the overall accuracy of the assay can be seen as a weighted mean coefficient of deviation of 4.6%.
The level of atracurium in the batch at the time of manufacture was 113.5%, a concentration of 11.35 mg/ml, with a level of related substances of less than 8.0%. Thus in this batch, the level of atracurium approximately four months beyond the Figure 2 ). The relationship between ambient exposure and atracurium potency is highly correlated (r = 0.95) and expressed by the linear equation A = 101.7 -0.08298D where A is % of atracurium, and D is time in days. DISCUSSION This study shows that three months' exposure to ambient temperature will not substantially reduce the potency of atracurium. Even if the initial strength is only 105%, which is the lower level of The estimates of remaining strength given by this study will be slightly lower than might occur in practice as the batch of atracurium used for the study was actually about four months beyond its expiry date when finally assayed. In any case, the normal variation in clinical susceptibility to relaxant makes it unlikely that the difference between 90% and 100% strength would be noticed in clinical practice. The degradation of atracurium in the body at 37"C and pH 7.3 is about three times faster in plasma than in a simple buffer solution. 1 However, even the simple buffer results in a half-life of about one hour. It is interesting that on theoretical grounds our results are to be expected. Two influences, temperature and pH, can degrade atracurium in a simple solution without any enzyme activity. If the linear regression slope of 0.083% per day is used as an approximation of the initial exponential decay to calculate a half-life at 20°C, the result is 766 days. Exposure to 37°C with a QlO of approximately 2.5 for organic reactions gives a new half-life of 161 days, i.e. a 4.6 fold enhancement. These calculations emphasise the small role which temperature plays in the usual degradation of atracurium. In contrast, a pH change from 3.3 to pH 7.3, as can be seen from the work of Stiller and his colleagues,l which has already been mentioned, reduces the measured half-life to about an hour, i.e. about a 4000 fold enhancement. This can be explained by the change in hydrogen acceptance. If the rate of proton, i.e. hydrogen ion, acceptance is inversely proportional to the concentration of hydrogen ion, then the breakdown tendency, which is a proton acceptor event, must be increased about 10,000 times. (The difference between logarithm 7.3 and 3.3.) Finally, the actual measured half-life in normal man is about twenty minutes. 2 This normal degradation appears to be best accounted for by the combined effect of plasma activity, presumably enzymatic, although not necessarily plasma cholinesterase, and the marked pH change from the pharmaceutical formulation. The modest temperature change would appear to play only a minor role in the normal elimination.
